Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells
- 17 July 2000
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1497 (2) , 215-226
- https://doi.org/10.1016/s0167-4889(00)00062-8
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Cellular survival: a play in three AktsGenes & Development, 1999
- Selective changes in EGF receptor expression and function during the proliferation, differentiation and apoptosis of mammary epithelial cellsEuropean Journal of Cell Biology, 1999
- Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.Journal of Clinical Pathology, 1998
- Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transductionNature, 1995
- The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathwayCell, 1995
- Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal AntibodiesJNCI Journal of the National Cancer Institute, 1993
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992
- In vitro effect of doxorubicin on non-proliferating and proliferating epithelial cellsInternational Journal of Radiation Oncology*Biology*Physics, 1990
- PREDICTIVE VALUE OF EGF RECEPTOR IN BREAST CANCERThe Lancet, 1988
- Human epidermal growth factor precursor: cDNA sequence, expressionin vitroand gene organizationNucleic Acids Research, 1986